XML 70 R27.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2015
Accounting Policies [Abstract]  
Schedule of Significant Balance of Accounts Receivable

The Company has not experienced any loss on its deposits of cash and cash equivalents. Included in current assets are significant balances of accounts receivable as follows:

 

 

 

As of December 31,

 

 

 

2015

 

 

2014

 

Astellas Pharma Inc. (“Astellas”)—Related party

 

 

29

%

 

 

37

%

AstraZeneca AB (“AstraZeneca”)

 

 

71

%

 

 

63

%